Buy LLY by Aug 24, 2026.

**"A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia"** [https://investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88](https://investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88) Forget the stock price, the implications for increase in longevity for a big chunk of the population is huge! Hope the next stage of trials goes through smoothly. This is big. *"They've gone and made what seems to be a powerful, permanent gene therapy for LDL …